Dalton Transactions

doi: 10.1039/C8DT90081Gpmid: N/A

doi: 10.1039/c8dt90081gpmid: N/A

doi: 10.1039/C8DT90082Epmid: N/A

doi: 10.1039/c8dt90082epmid: N/A

doi: 10.1039/c8dt90083cpmid: N/A

doi: 10.1039/C8DT90083Cpmid: N/A

Oun, Rabbab; Moussa, Yvonne E.; Wheate, Nial J.

doi: 10.1039/c8dt00838hpmid: 29632935

The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose-limiting side effects (also referred to as adverse effects/events). In total, a cancer patient can experience any combination of around 40 specific side effects. The dose-limiting side effect for cisplatin is nephrotoxicity, for carboplatin it is myelosuppression, and for oxaliplatin it is neurotoxicity. Other common side effects include anaphylaxis, cytopenias (including leukopenia and neutropenia, thrombocytopenia, and anaemia), hepatotoxicity, ototoxicity, cardiotoxicity, nausea and vomiting, diarrhea, mucositis, stomatitis, pain, alopecia, anorexia, cachexia, and asthenia. The side effects may require patients to be prescribed dose reductions in their platinum drugs of between 25 and 100%. Furthermore, patients require extensive monitoring of their biochemistries, kidney and liver function, and depending on the drug, hearing tests. Finally, patients are commonly co-prescribed additional non-chemotherapy based drugs to treat the side effects which can include antiemetics, antibiotics and myeloid growth factors, mannitol, propafenone, saline hyperhydration, magnesium supplements, monoclonal antibody cytokine blockers, and antioxidants.

Schmittel, Michael

doi: 10.1039/c8dt01010bpmid: 29664102

This personal frontier account describes our recent progress in networking nanoswitches to generate emergent functions, such as catalytic machinery, and identifies the key impediments in mastering the paradigm shift from pure compounds to smart mixtures. A crucial challenge is the setup of reliable signaling protocols that are based on highly selective metal ion translocation and metal–ligand receptor events.

Kang, Philjae; Mai, Hien Duy; Yoo, Hyojong

doi: 10.1039/c8dt00747kpmid: 29671852

A cobalt (Co) supramolecular triple-stranded helicate, [Co8(PDA)6(Br-PTA)3(DMF)4(H2O)2] (1) (PDA = 2,6-pyridinedicarboxylate, Br-PTA = 5-bromoisophthalate, DMF = dimethylformamide), is successfully synthesized and fully characterized. The solid-state structure of 1 shows that four cobalt atoms are coordinated by three PDA ligands to form a tetranuclear cobalt cluster with three extension points and the ditopic Br-PTA ligands interlink two basic assembly units. In crystal packing, the bromo group is surrounded by the cavity-like tetranuclear cobalt cluster, which acts as a metallocavitand, to generate a unique cage-like crystal packing geometry. The isomorphous molecular cage, which exhibits a similar crystal-packing geometry as observed in 1, is also successfully isolated. This is an unusual example of a highly symmetric cage-like crystal packing architecture, resulting from the interaction among metallocavitands of in situ generated supramolecular modules.

Rädisch, Tim; Harmgarth, Nicole; Liebing, Phil; Beltrán-Leiva, Maria J.; Páez-Hernández, Dayán; Arratia-Pérez, Ramiro; Engelhardt, Felix; Hilfert, Liane; Oehler, Florian; Busse, Sabine; Edelmann, Frank T.

doi: 10.1039/c8dt01064a